Summit Therapeutics (SMMT) EBIT (2017 - 2024)
Summit Therapeutics (SMMT) posted quarterly EBIT of -$65.6 million for Q4 2024, down 81.2% year-on-year from -$349.1 million in Q1 2024, and down 12.4% on a QoQ basis from -$58.4 million in Q3 2024.
Summit Therapeutics (SMMT) EBIT (2017 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has reported EBIT for 8 consecutive years, with -$65.6 million the latest figure, recorded in Q4 2024.
- Quarterly EBIT fell 81.2% year-over-year to -$65.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$226.0 million (up 62.93% YoY) and the FY2024 annual result came in at -$226.0 million, up 62.93% from the prior year.
- EBIT declined to -$65.6 million in Q4 2024 per SMMT's latest filing, from -$58.4 million in the prior quarter.
- Over the last five years, EBIT for SMMT reached as high as -$11.6 million in Q4 2020 and fell as low as -$537.2 million in Q1 2023.
- A 5-year average of -$52.9 million and a median of -$20.6 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2023 — EBIT sank 2324.2% — and 2024, when it surged 92.11%.
- Year by year, EBIT stood at -$11.6 million in 2020, then sank by 125.4% to -$26.0 million in 2021, then increased by 22.07% to -$20.3 million in 2022, then sank by 78.38% to -$36.2 million in 2023, then plunged by 81.2% to -$65.6 million in 2024.
- According to Business Quant data, EBIT over the past three periods registered -$65.6 million, -$58.4 million, and -$59.6 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Summit Therapeutics | 11.62 Bn | 11.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -65.61 Mn |
| Sep 30, 2024 | -58.38 Mn |
| Jun 30, 2024 | -59.62 Mn |
| Mar 31, 2024 | -42.39 Mn |
| Dec 31, 2023 | -36.21 Mn |
| Sep 30, 2023 | -20.49 Mn |
| Jun 30, 2023 | -15.79 Mn |
| Mar 31, 2023 | -537.15 Mn |
| Dec 31, 2022 | -20.30 Mn |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -12.69 Mn |
| Mar 31, 2022 | -22.16 Mn |
| Dec 31, 2021 | -26.05 Mn |
| Sep 30, 2021 | -19.49 Mn |
| Jun 30, 2021 | -23.73 Mn |
| Mar 31, 2021 | -16.92 Mn |
| Dec 31, 2020 | -11.56 Mn |
| Sep 30, 2020 | -16.94 Mn |
| Jun 30, 2020 | -15.36 Mn |
| Mar 31, 2020 | -20.77 Mn |